Topiramate

Mechanism

Chemical and Commercial Profile

Common trade names: Topamax, Fasarax, Topiramate Normon.
Group: Broad-spectrum antiepileptic, monosaccharide derivative substituted by sulfamate.

Mechanism of Action

Topiramate is a pleiotropic antiepileptic with multiple molecular mechanisms identified:

1. Blockade of voltage-gated sodium channels (Na_v): Stabilizes neurons by limiting prolonged repetitive firing.
2. Facilitation of GABAergic neurotransmission: Binds to a specific allosteric site on the GABA_A receptor and increases cellular entry of chloride (Cl^-), even independently of the benzodiazepine site.
3. AMPA/Kainate-type glutamate receptor antagonism: Selectively depresses presynaptic excitatory synaptic transmission.
4. Selective inhibition of carbonic anhydrase isoenzymes (type II and IV): Blocks the peripheral and cerebral conversion of carbon dioxide and water to bicarbonate, causing a mild metabolic acidosis that depresses cellular excitability.

Pharmacokinetics

Pharmacokinetics

• Absorption: Rapid and complete after oral intake; bioavailability of 80%. It is not altered by food. The plasma peak is reached after 2-3 hours.
• Distribution: Moderate binding to plasma proteins (15-20%). The volume of distribution is 0.6-0.8 L/kg. It easily crosses the blood-brain barrier.
• Metabolism: Limited oxidative hepatic (20%) via hydroxylation and glucuronidation. The remaining 80% of the absorbed dose is eliminated unchanged without undergoing hepatic enzymatic degradation.
• Excretion: Renal predominantly by glomerular filtration in unchanged form (80%).
• Half-life (t_1/2): 20 to 30 hours; Ideal for administration divided into two daily doses.

Indicators and dose

Indications

• Monotherapy and adjuvant therapy in focal and generalized tonic-clonic seizures.
• Treatment of seizures associated with Lennox-Gastaut Syndrome.
• First-line treatment in Prophylaxis of Chronic Migraine in adults.
• Off-label: Weight loss associated with binge eating disorders, essential tremor.

Dosage and Settings

• Standard Qualification (Adults):
  • Week 1: 25 mg once daily in the evening.
  • Week 2: 25 mg twice daily (50 mg/day).
  • Subsequent weeks: Increase 25-50 mg weekly progressively.
• Usual therapeutic range: 100-200 mg/day (in migraine); 200-400 mg/day (in epilepsy, divided into two doses).
• Renal Failure: In patients with creatinine clearance Cl_Cr < 70 ml/min, the starting and maintenance dose should be reduced to 50% of the standard.
• Liver Failure: Does not require complex dose adjustments in Child-Pugh A or B liver disease; extreme caution in Child-Pugh C.

Security

Contraindications

• Hypersensitivity to the active ingredient or to compounds with a sulfonamide structure.
• Migraine prophylaxis in pregnant women or women of childbearing age who do not use highly effective contraceptives.

Adverse Effects (ADR)

Cognitive Alert · The "Dopamax" Syndrome

Topiramate presents a very common adverse neurocognitive profile that associates **psychomotor slowing, difficulty concentrating, confusion, bradypsychia and significant problems finding words (transient dysnomia)**. These effects are dependent on the rate of dose escalation and can severely limit the patient's professional performance. They are controlled by a slow titration regimen.

• Metabolic / Ophthalmic: Hyperchloremic metabolic acidosis with normal anion gap, calcium phosphate and oxalate nephrolithiasis (in 1.5% of patients due to elevated urinary pH secondary to carbonic anhydrase blockade), rapid-onset transient symmetric acute narrow-angle glaucoma (ophthalmic urgency).
• General: Marked weight loss (induced anorexia), distal symmetrical paresthesias (continuous tingling of the hands and feet due to inhibition of tissue carbonic anhydrase), marked decrease in sweating (anhidrosis and hyperthermia).

Clinical Interactions

• Selective Inhibition and Induction: It weakly inhibits the CYP2C19 isoenzyme (increases levels of phenytoin) and moderately induces the CYP3A4 isoenzyme (decreases levels of oral contraceptives at doses >200 mg/day).
• With other AEDs: Carbamazepine or phenytoin reduce the concentration of topiramate by 50% by inducing its renal clearance.

Pregnancy and Breastfeeding

FDA Category: D. Demonstrated high risk of induction of orofacial malformations (cleft lip and palate) of up to 3% in pregnancies exposed in the first trimester, in addition to low gestational weight. Breastfeeding: Compatible with caution; It is excreted in milk in moderate concentrations. Monitor drowsiness or diarrhea in the infant.